Antibodies
7 February 2013
biOasis Announces Positive Anti-Tumour Efficacy Data7 February 2013
Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer’s Model for Its TauC3 Monoclonal Antibody7 February 2013
Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results6 February 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI from Elan for Upfront Cash and Contingent Payments6 February 2013
Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A5 February 2013
Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer5 February 2013
Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma5 February 2013
ZALTRAP (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer4 February 2013
Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX4031 January 2013
Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)29 January 2013
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes28 January 2013
Results from Active Biotech’s Phase II/III ANYARA trial for the treatment of renal cell cancer27 January 2013
Seattle Genetics Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer24 January 2013
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer23 January 2013
Synthon Biopharmaceuticals Reports Positive Early Results with Its Second Generation HER2-Antibody-Drug Conjugate16 January 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS11 January 2013
KaloBios Initiates Phase 2 Study with KB001-A Humaneered Monoclonal Antibody in Cystic Fibrosis Patients11 January 2013
EISAI ANNOUNCES RESULTS OF PHASE III STUDY OF ANTICANCER AGENT FARLETUZUMAB IN PATIENTS WITH RELAPSED PLATINUM-SENSITIVE OVARIAN CANCER8 January 2013
Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand8 January 2013
arGEN-X Initiates Phase Ib Study of ARGX-110 in CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports